Gilead Sciences (GILD) Accumulated Expenses (2009 - 2026)
Gilead Sciences' (GILD) quarterly Accumulated Expenses came in at $4.1 billion in Q1 2026, down 1.6% YoY from $4.2 billion in Q1 2025, and down 5.05% on a QoQ basis from $4.3 billion in Q4 2025.
Gilead Sciences (GILD) Accumulated Expenses (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Accumulated Expenses data on file, last reported at $4.1 billion in Q1 2026.
- Quarterly Accumulated Expenses fell 1.6% year-over-year to $4.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 billion (down 1.6% YoY) and the FY2025 annual result came in at $4.3 billion, up 11.43% from the prior year.
- Accumulated Expenses eased to $4.1 billion in Q1 2026, from $4.3 billion in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $4.9 billion in Q3 2025 to a low of $3.4 billion in Q1 2022.
- A 5-year average of $4.0 billion and a median of $3.9 billion in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses advanced 25.08% — and 2023, when it dropped 15.09%.
- Tracing GILD's Accumulated Expenses over 5 years: stood at $3.5 billion in 2022, then rose by 9.28% to $3.8 billion in 2023, then gained by 2.37% to $3.9 billion in 2024, then increased by 11.43% to $4.3 billion in 2025, then declined by 5.05% to $4.1 billion in 2026.
- The last three Accumulated Expenses figures came in at $4.1 billion (Q1 2026), $4.3 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.23 Bn |
| Mar 31, 2026 | 4.12 Bn |
| Dec 31, 2025 | 4.34 Bn |
| Sep 30, 2025 | 4.93 Bn |
| Jun 30, 2025 | 4.22 Bn |
| Mar 31, 2025 | 4.19 Bn |
| Dec 31, 2024 | 3.89 Bn |
| Sep 30, 2024 | 4.11 Bn |
| Jun 30, 2024 | 3.92 Bn |
| Mar 31, 2024 | 4.26 Bn |
| Dec 31, 2023 | 3.80 Bn |
| Sep 30, 2023 | 3.71 Bn |
| Jun 30, 2023 | 3.49 Bn |
| Mar 31, 2023 | 3.48 Bn |
| Dec 31, 2022 | 3.48 Bn |
| Sep 30, 2022 | 3.67 Bn |
| Jun 30, 2022 | 4.12 Bn |
| Mar 31, 2022 | 3.45 Bn |
| Dec 31, 2021 | 3.24 Bn |
| Sep 30, 2021 | 3.37 Bn |